AIMCo joins $35 mln funding of molecular diagnostics company CardioDx

U.S. molecular diagnostics company CardioDx Inc has secured US$35 million in new financing. Canadian pension fund manager Alberta Investment Management Corp (AIMCo) participated in the round along with existing investors. Based in Redwood City, California, CardioDX specializes in cardiovascular genomics, and is focused on developing clinically validated tests that help clinicians care for patients. The company, which is reported to have raised US$21 million in July, is backed by Artiman Ventures, Kleiner Perkins Caufield & Byers, Longitude Capital, Mohr Davidow Ventures, Pappas Ventures and Temasek Life Sciences, among others.

CanadaNorth AmericaBriefs